Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
358 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06458244 | The Efficacy of Allo-HSCT in ND HR-CBF-AML | recruiting | — | 90 | Ruijin HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07525024 | KSD-101 in Patients With EBV-associated Hematological Malignancies | not yet recruiting | — | 80 | Ruijin HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07493330 |
| Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL |
| not yet recruiting |
| Phase 1 / Phase 2 |
| 86 |
| Ruijin HospitalOTHER |
| 0 |
| Apr 7, 2026 |
| clinicaltrials |
| NCT07511114 | A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping | not yet recruiting | Phase 3 | 156 | Ruijin HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511127 | Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT | recruiting | Phase 3 | 218 | Ruijin HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07504471 | Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases | recruiting | Phase 2 | 50 | Ruijin HospitalOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07331883 | Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) | recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07498855 | Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation(RADIANT) | recruiting | — | 25 | Ruijin HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06793189 | MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL | recruiting | Phase 2 | 145 | Ruijin HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07380984 | PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL | recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07461181 | A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 10 | Ruijin HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07450963 | Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT | not yet recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 0 | Mar 5, 2026 | clinicaltrials |
| NCT07405255 | Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma(Zillion) | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06693128 | Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer | active not recruiting | Phase 2 | 80 | Ruijin HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06069830 | PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma(ENKTL) | recruiting | N/A | 89 | Ruijin HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07366528 | Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer | recruiting | Phase 3 | 387 | Ruijin HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04208347 | Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer | active not recruiting | Phase 2 / Phase 3 | 580 | Ruijin HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07232433 | Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules | recruiting | N/A | 90 | Ruijin HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04509648 | Adjuvant Regional Nodal Radiation Therapy for One Week in Breast Cancer(ARROW) | active not recruiting | N/A | 197 | Ruijin HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07342725 | Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 48 | Ruijin HospitalOTHER | 0 | Jan 15, 2026 | clinicaltrials |
| NCT07334574 | Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL(XP-006) | not yet recruiting | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07326358 | AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study | recruiting | — | 500 | Ruijin HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | not yet recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 0 | Jan 8, 2026 | clinicaltrials |
| NCT06365671 | CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors | recruiting | Phase 2 | 16 | Ruijin HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07306273 | IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07306286 | Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07301138 | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | not yet recruiting | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04400357 | Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors(PORTAL) | completed | N/A | 268 | Ruijin HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07283991 | QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer(BRICES) | not yet recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 0 | Dec 16, 2025 | clinicaltrials |
| NCT07285174 | Shanghai Lymphoma Clinical Cohort | not yet recruiting | — | 1,000 | Ruijin HospitalOTHER | 0 | Dec 16, 2025 | clinicaltrials |
| NCT06449586 | CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT | active not recruiting | Phase 3 | 250 | Ruijin HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07279584 | Golidocitinib Combined With GemOx in RR PTCL | not yet recruiting | Phase 2 | 31 | Ruijin HospitalOTHER | 0 | Dec 12, 2025 | clinicaltrials |
| NCT07269587 | A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 | active not recruiting | — | 275 | Ruijin HospitalOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07238907 | A Multi-center Retrospective Study of INO Treating B-ALL | active not recruiting | — | 102 | Ruijin HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06496373 | Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer | recruiting | Early Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07209163 | Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Ruijin HospitalOTHER | 0 | Oct 6, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06368141 | Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer(NeoCHIC) | recruiting | Phase 2 | 56 | Ruijin HospitalOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT07122609 | Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 22 | Ruijin HospitalOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06458257 | The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia | recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07080021 | A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer(MRD) | recruiting | — | 119 | Ruijin HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07091006 | Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML | not yet recruiting | Phase 2 | 44 | Ruijin HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07087847 | Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia | not yet recruiting | N/A | 18 | Ruijin HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials